TSTakeshi Sano

Takeshi Sano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Sano has a total of 266 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reconsidering the terminology of “early” and “advanced” gastric cancer: toward a harmonized global lexicon

    by Takeshi Sano, Narikazu Boku, Florian Lordick

    The term early gastric cancer (EGC) , defined as carcinoma confined to the mucosa or submucosa irrespective of lymph node status, has been widely accepted worldwide. In contrast, the terminology surrounding advanced gastric cancer remains inconsistent across regions. In Western oncology, “advanced cancer” often denotes unresectable or metastatic disease, whereas “early-stage cancer” may include resectable stage II–III tumors. This semantic discrepancy has led to confusion in international communication, clinical trials, and guideline interpretation. We propose a three-tier terminology— early gastric cancer , locally advanced gastric cancer , and advanced gastric cancer —to align the Japanese pathological concept with global clinical staging practice and therapeutic intent.


  • Open Access

    Patients participation in multidisciplinary management in gastric cancer: regulation comparison and expert survey among major countries

    by Kyoyoung Park, Hyuk-Joon Lee, Seong-Ho Kong, Do Joong Park, Hyunsoo Chung, Soo-Jeong Cho, Seock-Ah Im, Yoonjin Kwak, Hye Seung Lee, Eui Kyu Chie, et al.

    Purpose: In Korea, the Health Insurance Review and Assessment Service (HIRA) mandates patient participation in outpatient multidisciplinary team (MDT) meetings as part of national cancer quality assessment. However, the necessity of involving patients and families in MDT discussions remains debatable. This study explored international expert perspectives on patient participation in gastric cancer MDTs.Methods: A cross-national expert survey was conducted in September 2021 among 15 gastric cancer specialists from Korea, China, Japan, Singapore, and the United States. The survey assessed the frequency of patient and family member attendance, perceived pros and cons, and preferences regarding mandatory versus selective involvement. Additionally, MDT structures and policies were reviewed by countries.Results: Most respondents reported that patients and families rarely or never attend MDT meetings: nine stated that patients are never included, three reported “usually not,” and three indicated “sometimes.” None consistently included patients. The most cited benefits were sharing opinions with patients and families simultaneously, followed by improved explanation of treatment and legal protection. Major concerns included hindered discussion, inefficiency, and logistical challenges. Only four respondents supported routine participation, while 11 favored case-dependent involvement.Conclusion: International experts do not widely support mandatory patient participation in MDT meetings. A flexible approach that allows MDTs to operate with or without patient involvement may better reflect actual clinical practice.


  • Open Access

    Prealbumin Prognostic Score: A Novel Prognostic Indicator After Radical Gastrectomy in Patients with Gastric Cancer

    by Ryota Matsui, Souya Nunobe, Motonari Ri, Rie Makuuchi, Tomoyuki Irino, Masaru Hayami, Manabu Ohashi, Takeshi Sano

    Background: This study aimed to determine whether the prealbumin prognostic score (PPS), a novel indicator using prealbumin instead of albumin in the modified Glasgow Prognostic Score (mGPS), is a better predictive marker postoperatively in patients with gastric cancer. Methods: This retrospective study included consecutive patients who underwent radical gastrectomy for primary pStages I–III gastric cancer between 2006 and 2017. The cutoff values for preoperative prealbumin and C-reactive protein (CRP) were 22 mg/dL and 0.5 mg/dL, respectively. According to the prealbumin and CRP levels, a PPS of zero was defined as both being above the cutoff value, of one as either being below the cutoff value, and of two as both being below the cutoff value. Results: Of the 4663 patients, 3421 (73.4%) had a score of zero, 984 (21.1%) had a score of one, and 258 (5.5%) had a score of two. The higher the PPS, the poorer the overall survival [OS] (p < 0.001). When comparing OS by the PPS in patients with an mGPS of zero, a PPS of one indicated poorer OS than a PPS of zero (p < 0.001). In the multivariate analysis, PPSs of one (hazard ratio [HR]: 1.603; 95% confidence interval [CI]: 1.378–1.866; p < 0.001) and two (HR: 1.322; 95% CI: 1.055–1.656; p = 0.015) were independent poor prognostic factors for OS. Conclusions: The PPS, which is based on a combination of prealbumin and CRP levels, can identify a wider range of patients with poor OS than mGPS in patients with gastric cancer after gastrectomy.


  • Open Access

    Reconstruction Techniques and Associated Morbidity in Minimally Invasive Gastrectomy for Cancer

    by Marcel André Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P. Grimminger, Bas P. L. Wijnhoven, Hidde Overtoom, Ines Gockel, René Thieme, Ewen A. Griffiths, et al.

    Objective/Background: Various anastomotic and reconstruction techniques are used for minimally invasive total (miTG) and distal gastrectomy (miDG). Their effects on postoperative morbidity have not been extensively studied. Methods: MiTG and miDG patients were selected from 9356 oncological gastrectomies performed in 2017–2021 in 43 centers. Endpoints included anastomotic leakage (AL) rate and postoperative morbidity tested by multivariable analysis. Results: Three major anastomotic techniques [circular stapled (CS); linear stapled (LS); and hand sewn (HS)], and 3 major bowel reconstruction types [Roux (RX); Billroth I (BI); Billroth II (BII)] were identified in miTG (n=878) and miDG (n=3334). Postoperative complications, including AL (5.2% vs 1.1%), overall (28.7% vs 16.3%), and major morbidity (15.7% vs 8.2%), as well as 90-day mortality (1.6% vs 0.5%) were higher after miTG compared with miDG. After miTG, the AL rate was higher after CS (4.3%) and HS (7.9%) compared with LS (3.4%). Similarly, major complications (LS: 9.7%, CS: 16.2%, and HS: 12.7%) were lowest after LS. Multivariate analysis confirmed anastomotic technique as a predictive factor for AL, overall, and major complications. In miDG, AL rate (BI: 1.4%, BII 0.8%, and RX 1.2%), overall (BI: 14.5%, BII: 15.0%, and RX: 18.7%), and major morbidity (BI: 7.9%, BII: 9.1%, and RX: 7.2%), and mortality (BI: 0%, BII: 0.1%, and RY: 1.1%%) were not affected by bowel reconstruction. Conclusions: In oncologically suitable situations, miDG should be preferred to miTG, as postoperative morbidity is significantly lower. LS should be a preferred anastomotic technique for miTG in Western Centers. Conversely, bowel reconstruction in DG may be chosen according to the surgeon’s preference.


  • Open Access

    Clinical Impact of Polyglycolic Acid Mesh to Reduce Pancreas-Related Complications After Minimally Invasive Surgery for Gastric Cancer: A Propensity Score Matching Analysis

    by Motonari Ri, Manabu Ohashi, Rie Makuuchi, Masaru Hayami, Takeshi Sano, Souya Nunobe

    Ri M, et al. J Gastric Cancer. 2024 Apr;24(2):220-230. https://doi.org/10.5230/jgc.2024.24.e17


  • Open Access

    Advantages of Function-Preserving Gastrectomy for Older Patients With Upper-Third Early Gastric Cancer: Maintenance of Nutritional Status and Favorable Survival

    by Masayoshi Terayama, Manabu Ohashi, Satoshi Ida, Masaru Hayami, Rie Makuuchi, Koshi Kumagai, Takeshi Sano, Souya Nunobe

    Terayama M, et al. J Gastric Cancer. 2023 Jan;23:e9. https://doi.org/10.5230/jgc.2023.23.e9


  • Open Access

    Successful open radical gastrectomy for locally advanced or metastatic gastric cancer patients who suffered from coronavirus disease 2019 during preoperative chemotherapy: a report of three cases

    by Naoki Nishie, Manabu Ohashi, Rie Makuuchi, Masaru Hayami, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Takeshi Sano

    Background: According to previous reports, in patients with preoperative coronavirus disease 2019 (COVID-19) infection, mortality is increased if they undergo surgery within 6 weeks of diagnosis. However, the optimal timing and preoperative examination for gastrectomy with a previous COVID-19 infection are still controversial. We experienced three cases in which patients successfully underwent open radical gastrectomy following preoperative chemotherapy even though they developed COVID-19 infection during the chemotherapy. Case presentation: Case 1: A 58-year-old man with locally advanced gastric cancer caught COVID-19 during preoperative chemotherapy comprising 5-fluorouracil, calcium folate, oxaliplatin, and docetaxel. Although the patient had specific lung shadows indicating COVID-19 infection and deep venous thrombosis in the lower extremities, he underwent distal gastrectomy 10 weeks after the COVID-19 diagnosis. He had a good postoperative course. Case 2: A 56-year-old man with gastric cancer and lymph node and peritoneal metastasis caught COVID-19 during palliative chemotherapy comprising S-1, oxaliplatin, and trastuzumab. He underwent total gastrectomy as conversion surgery 8 weeks after COVID-19 infection. His postoperative course was uneventful. Case 3: A 55-year-old man with gastric cancer and paraaortic lymph node and liver metastases caught COVID-19 during S-1 and oxaliplatin treatment as neoadjuvant chemotherapy. He underwent distal gastrectomy, paraaortic lymph node sampling, and partial hepatectomy 8 weeks after COVID-19 infection although he had residual lung shadows and deep venous thrombosis in the lower extremities. He had an uneventful postoperative course. Conclusions: Computed tomography for preoperative evaluation was performed for all three patients and revealed that lung shadows remained post-COVID-19 infection. Despite this finding, the patients had good operative courses and were discharged as planned. Surgery after 7 weeks from the diagnosis of COVID-19 infection can be performed safely even when patients are post-chemotherapy and have residual lung findings and deep venous thrombosis. This report may contribute to the development of a consensus on performing safe gastrectomy for advanced gastric cancer in patients previously infected with COVID-19.


  • Open Access

    Postprandial Asymptomatic Glycemic Fluctuations after Gastrectomy for Gastric Cancer Using Continuous Glucose Monitoring Device

    by Motonari Ri, Souya Nunobe, Satoshi Ida, Naoki Ishizuka, Shinichiro Atsumi, Masaru Hayami, Rie Makuuchi, Koshi Kumagai, Manabu Ohashi, Takeshi Sano

    Ri M, et al. J Gastric Cancer. 2021 Nov;21:e31. https://doi.org/10.5230/jgc.2021.21.e31


  • Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan

    by Tomoyuki Irino, Takeshi Sano, Naoki Hiki, Manabu Ohashi, Souya Nunobe, Koshi Kumagai, Satoshi Ida, Toshiharu Yamaguchi

    There have been many studies that describe the value of diagnostic staging laparoscopy (DSL) in gastric cancer. However, different studies use different indications, making study results difficult to compare. This study aimed to clarify the diagnostic feasibility of DSL for gastric cancer in a prospective manner and investigated the impact of DSL on clinical decision-making in gastric cancer treatment.